SEEL Key Statistics, Chart & Performance
The current stock price of SEEL is 1.28 USD. In the past month the price decreased by -64.44%. In the past year, price decreased by -99.83%.
SEEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About SEEL
Company Profile
Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 10 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
Company Info
SEELOS THERAPEUTICS INC
300 Park Avenue, 2nd Floor
New York City NEW YORK 10022 US
CEO: Raj Mehra
Employees: 8
Phone: 16462932100
SEELOS THERAPEUTICS INC / SEEL FAQ
What does SEELOS THERAPEUTICS INC do?
Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 10 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
Can you provide the latest stock price for SEELOS THERAPEUTICS INC?
The current stock price of SEEL is 1.28 USD. The price decreased by -47.76% in the last trading session.
Does SEELOS THERAPEUTICS INC pay dividends?
SEEL does not pay a dividend.
How is the ChartMill rating for SEELOS THERAPEUTICS INC?
SEEL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is SEEL stock listed?
SEEL stock is listed on the Nasdaq exchange.
What is the market capitalization of SEEL stock?
SEELOS THERAPEUTICS INC (SEEL) has a market capitalization of 563.20K USD. This makes SEEL a Nano Cap stock.
Who owns SEELOS THERAPEUTICS INC?
You can find the ownership structure of SEELOS THERAPEUTICS INC (SEEL) on the Ownership tab.
SEEL Technical Analysis
SEEL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SEEL. Both the profitability and financial health of SEEL have multiple concerns.
SEEL Financial Highlights
Over the last trailing twelve months SEEL reported a non-GAAP Earnings per Share(EPS) of -45.32. The EPS decreased by -318.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 203.13% | ||
| ROA | 171.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SEEL Forecast & Estimates
7 analysts have analysed SEEL and the average price target is 122.4 USD. This implies a price increase of 9462.5% is expected in the next year compared to the current price of 1.28.
For the next year, analysts expect an EPS growth of 97.05% and a revenue growth -81.25% for SEEL